TrialJournal of hematology & oncology2024

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

Timothy P Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.